Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An extension study

all contributing centers (www.eltr.org); the European Liver and Intestine Transplant Association (ELITA)

doi:10.1097/TP.0000000000002700

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An extension study

all contributing centers (www.eltr.org)
, the European Liver and Intestine Transplant Association (ELITA)

Department of Anesthesiology and Intensive Care

Biochimie et Oncogénétique
Institute for Clinical and Experimental Medicine
University of Rome Tor Vergata
Centre of Cardiovascular Surgery and Transplantation
AP-HP
Medical University Innsbruck
Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione)
Klinikum der J. W. Goethe-Universität
Udine University Hospital
Oslo University Hospital
Università di Ancona
Umberto 1 Policlinico of Rome
Leuven University Center for Metabolic Bone Diseases
Hannover Medical School
Republican Scientific and Practical Center (RSPC) for Organ and Tissue Transplantation
University of Modena and Reggio Emilia
Medical University of Warsaw
Ghent University Hospital
University Hospital of Essen
Tartu University Hospital
University Medical Center
CHU Pontchaillou
St Vincent's University Hospital
Pope John XXIII Hospital
Charité – Universitätsmedizin Berlin
Johannes Gutenberg University
Central Military Emergency University Hospital
Karolinska Institutet at Karolinska University Hospital
Vilnius University
University Hospital
University Hospital
Hôpital de l’ARCHET I
DIBINEM, Alma Mater Studiorum, University of Bologna
Sahlgrenska University Hospital
Central Hospital of Oilworkers
Hôpital de Hautepierre
University of Edinburgh
Copenhagen University Hospital
University Hospital Zurich
St James and Seacroft University Hospital
King’s College Hospital
Ospedale Brotzu
Kent Hospital
Hôpital Henri Mondor

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Background. We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)–based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. Methods. Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T. Overall, 13 088 patients were included from 44 European centers; propensity score–matched analyses comprised 3006 patients (PR-T: n = 1002; IR-T: n = 2004). Results. In multivariate analyses, IR-T-based immunosuppression was associated with reduced graft survival (risk ratio, 1.49; P = 0.0038) and patient survival (risk ratio, 1.40; P = 0.0215). There was improvement with PR-T versus IR-T in graft survival (83% versus 77% at 4 y, respectively; P = 0.005) and patient survival (85% versus 80%; P = 0.017). Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate than patients receiving IR-T at last followup (P < 0.001), or started and maintained on PR-T (P = 0.019). One graft loss in 4 years was avoided for every 14.3 patients treated with PR-T versus IR-T. Conclusions. PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients than IR-T-based immunosuppression.

Original language	English
Pages (from-to)	1844-1862
Number of pages	19
Journal	Transplantation
Volume	103
Issue number	9
DOIs	https://doi.org/10.1097/TP.0000000000002700
State	Published - 1 Sep 2019

Access to Document

10.1097/TP.0000000000002700

Cite this

all contributing centers (www.eltr.org), & the European Liver and Intestine Transplant Association (ELITA) (2019). Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An extension study. Transplantation, 103(9), 1844-1862. https://doi.org/10.1097/TP.0000000000002700

@article{8af6349df7ef494daca739710b31a40a,

title = "Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An extension study",

abstract = "Background. We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)–based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. Methods. Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T. Overall, 13 088 patients were included from 44 European centers; propensity score–matched analyses comprised 3006 patients (PR-T: n = 1002; IR-T: n = 2004). Results. In multivariate analyses, IR-T-based immunosuppression was associated with reduced graft survival (risk ratio, 1.49; P = 0.0038) and patient survival (risk ratio, 1.40; P = 0.0215). There was improvement with PR-T versus IR-T in graft survival (83\% versus 77\% at 4 y, respectively; P = 0.005) and patient survival (85\% versus 80\%; P = 0.017). Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate than patients receiving IR-T at last followup (P < 0.001), or started and maintained on PR-T (P = 0.019). One graft loss in 4 years was avoided for every 14.3 patients treated with PR-T versus IR-T. Conclusions. PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients than IR-T-based immunosuppression.",

author = "\{all contributing centers (www.eltr.org)\} and \{the European Liver and Intestine Transplant Association (ELITA)\} and Ren{\'e} Adam and Vincent Karam and Val{\'e}rie Cailliez and Pavel Trune{\v c}ka and Didier Samuel and Giuseppe Tisone and Petr N{\v e}mec and Olivier Soubrane and Stefan Schneeberger and Bruno Gridelli and Bechstein, \{Wolf O.\} and Andrea Risaliti and Line, \{Pal Dag\} and Marco Vivarelli and Massimo Rossi and Jacques Pirenne and Klempnauer, \{Jurgen L.\} and Aleh Rummo and \{Di Benedetto\}, Fabrizio and Krzysztof Zieniewicz and Roberto Troisi and Andreas Paul and Toomas Vali and Otto Kollmar and Karim Boudjema and Emir Hoti and Michele Colledan and Johan Pratschke and Hauke Lang and Irinel Popescu and Ericzon, \{Bo Goran\} and Kestutis Strupas and \{de Simone\}, Paolo and Eberhard Kochs and Bruno Heyd and Jean Gugenheim and Pinna, \{Antonio D.\} and William Bennet and Mirjalal Kazimi and Philippe Bachellier and Wigmore, \{Stephen J.\} and Allan Rasmussen and Clavien, \{Pierre Alain\} and Ernest Hidalgo and O{\textquoteright}Grady, \{John G.\} and Frausto Zamboni and Murat Kilic and Christophe Duvoux",

year = "2019",

month = sep,

day = "1",

doi = "10.1097/TP.0000000000002700",

language = "English",

volume = "103",

pages = "1844--1862",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

all contributing centers (www.eltr.org) & the European Liver and Intestine Transplant Association (ELITA) 2019, 'Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An extension study', Transplantation, vol. 103, no. 9, pp. 1844-1862. https://doi.org/10.1097/TP.0000000000002700

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An extension study. / all contributing centers (www.eltr.org); the European Liver and Intestine Transplant Association (ELITA).
In: Transplantation, Vol. 103, No. 9, 01.09.2019, p. 1844-1862.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR)

T2 - An extension study

AU - all contributing centers (www.eltr.org)

AU - the European Liver and Intestine Transplant Association (ELITA)

AU - Adam, René

AU - Karam, Vincent

AU - Cailliez, Valérie

AU - Trunečka, Pavel

AU - Samuel, Didier

AU - Tisone, Giuseppe

AU - Němec, Petr

AU - Soubrane, Olivier

AU - Schneeberger, Stefan

AU - Gridelli, Bruno

AU - Bechstein, Wolf O.

AU - Risaliti, Andrea

AU - Line, Pal Dag

AU - Vivarelli, Marco

AU - Rossi, Massimo

AU - Pirenne, Jacques

AU - Klempnauer, Jurgen L.

AU - Rummo, Aleh

AU - Di Benedetto, Fabrizio

AU - Zieniewicz, Krzysztof

AU - Troisi, Roberto

AU - Paul, Andreas

AU - Vali, Toomas

AU - Kollmar, Otto

AU - Boudjema, Karim

AU - Hoti, Emir

AU - Colledan, Michele

AU - Pratschke, Johan

AU - Lang, Hauke

AU - Popescu, Irinel

AU - Ericzon, Bo Goran

AU - Strupas, Kestutis

AU - de Simone, Paolo

AU - Kochs, Eberhard

AU - Heyd, Bruno

AU - Gugenheim, Jean

AU - Pinna, Antonio D.

AU - Bennet, William

AU - Kazimi, Mirjalal

AU - Bachellier, Philippe

AU - Wigmore, Stephen J.

AU - Rasmussen, Allan

AU - Clavien, Pierre Alain

AU - Hidalgo, Ernest

AU - O’Grady, John G.

AU - Zamboni, Frausto

AU - Kilic, Murat

AU - Duvoux, Christophe

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background. We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)–based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. Methods. Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T. Overall, 13 088 patients were included from 44 European centers; propensity score–matched analyses comprised 3006 patients (PR-T: n = 1002; IR-T: n = 2004). Results. In multivariate analyses, IR-T-based immunosuppression was associated with reduced graft survival (risk ratio, 1.49; P = 0.0038) and patient survival (risk ratio, 1.40; P = 0.0215). There was improvement with PR-T versus IR-T in graft survival (83% versus 77% at 4 y, respectively; P = 0.005) and patient survival (85% versus 80%; P = 0.017). Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate than patients receiving IR-T at last followup (P < 0.001), or started and maintained on PR-T (P = 0.019). One graft loss in 4 years was avoided for every 14.3 patients treated with PR-T versus IR-T. Conclusions. PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients than IR-T-based immunosuppression.

AB - Background. We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)–based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. Methods. Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T. Overall, 13 088 patients were included from 44 European centers; propensity score–matched analyses comprised 3006 patients (PR-T: n = 1002; IR-T: n = 2004). Results. In multivariate analyses, IR-T-based immunosuppression was associated with reduced graft survival (risk ratio, 1.49; P = 0.0038) and patient survival (risk ratio, 1.40; P = 0.0215). There was improvement with PR-T versus IR-T in graft survival (83% versus 77% at 4 y, respectively; P = 0.005) and patient survival (85% versus 80%; P = 0.017). Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate than patients receiving IR-T at last followup (P < 0.001), or started and maintained on PR-T (P = 0.019). One graft loss in 4 years was avoided for every 14.3 patients treated with PR-T versus IR-T. Conclusions. PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients than IR-T-based immunosuppression.

UR - https://www.scopus.com/pages/publications/85071712569

U2 - 10.1097/TP.0000000000002700

DO - 10.1097/TP.0000000000002700

M3 - Article

C2 - 31343568

AN - SCOPUS:85071712569

SN - 0041-1337

VL - 103

SP - 1844

EP - 1862

JO - Transplantation

JF - Transplantation

IS - 9

ER -

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Registry (ELTR): An extension study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this